Novartis Ag (NVS) Receivables Refunds (2017 - 2025)
Novartis Ag's Receivables Refunds history spans 9 years, with the latest figure at $205.0 million for Q4 2025.
- For Q4 2025, Receivables Refunds rose 54.14% year-over-year to $205.0 million; the TTM value through Dec 2025 reached $205.0 million, up 54.14%, while the annual FY2025 figure was $205.0 million, 54.14% up from the prior year.
- Receivables Refunds for Q4 2025 was $205.0 million at Novartis Ag, up from $133.0 million in the prior quarter.
- Across five years, Receivables Refunds topped out at $426.0 million in Q4 2023 and bottomed at $133.0 million in Q4 2024.
- The 5-year median for Receivables Refunds is $268.0 million (2022), against an average of $262.0 million.
- The largest annual shift saw Receivables Refunds surged 58.96% in 2023 before it plummeted 68.78% in 2024.
- A 5-year view of Receivables Refunds shows it stood at $278.0 million in 2021, then dropped by 3.6% to $268.0 million in 2022, then soared by 58.96% to $426.0 million in 2023, then tumbled by 68.78% to $133.0 million in 2024, then surged by 54.14% to $205.0 million in 2025.
- Per Business Quant, the three most recent readings for NVS's Receivables Refunds are $205.0 million (Q4 2025), $133.0 million (Q4 2024), and $426.0 million (Q4 2023).